Trial intelligence / Profile preview

Alectinib in ALK-positive rare cancers

jRCT2091220364Completed

Sponsor

Yasushi Goto, Department of Thoracic Oncology, National Cancer Center Hospital

Start

Jul 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1